Company Overview

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for serious rare genetic diseases. The company operates within the biotechnology and pharmaceutical industries, with an emphasis on addressing conditions with high unmet medical need through advanced genetic medicine approaches. Its core strategy centers on developing one-time or limited-administration therapies intended to provide durable clinical benefit.

The company’s primary value driver is its gene therapy pipeline, most notably programs targeting inherited retinal diseases and rare pediatric disorders. Abeona has positioned itself as a specialist in adeno-associated virus (AAV)-based gene therapies and ex vivo cell therapies, leveraging internal manufacturing and development capabilities. Founded in 1974 and previously operating under different corporate structures and names, the company refocused its strategy in the mid-2010s toward rare disease gene therapy through asset acquisitions and internal research realignment.

Business Operations

Abeona’s operations are organized around research and development of gene and cell therapy candidates, with no commercialized products as of the latest public filings. Its lead program, ABO-504 (prademagene zamikeracel), is an AAV-based gene therapy designed for patients with Stargardt disease, a rare inherited retinal disorder. The company also has clinical and preclinical programs targeting other rare genetic conditions using both in vivo gene delivery and ex vivo cell therapy approaches.

Operations are primarily U.S.-based, with research, development, and clinical trial management conducted internally and through third-party contract research organizations. Abeona controls proprietary vector design technologies and maintains in-house current Good Manufacturing Practice (cGMP) gene therapy manufacturing capabilities, which it views as a strategic asset for both clinical development and potential commercialization. Revenue generation to date has primarily consisted of collaboration revenue, grants, and equity financing rather than product sales.

Strategic Position & Investments

Abeona’s strategic direction is centered on advancing late-stage clinical programs toward regulatory approval while strengthening its manufacturing infrastructure to support future commercialization. A key strategic initiative has been the continued investment in its internal gene therapy manufacturing facility to reduce reliance on external vendors and improve development timelines and cost control. The company prioritizes rare diseases with clear genetic etiology and defined regulatory pathways, particularly in ophthalmology.

Historically, Abeona expanded its pipeline through targeted acquisitions of gene therapy assets and platform technologies, integrating them into a unified rare disease strategy. While it does not operate as a diversified holding company, it maintains ownership of its intellectual property portfolio and wholly owned development programs rather than a broad portfolio of subsidiaries. Its emerging focus remains on advanced AAV vector engineering and scalable gene therapy production.

Geographic Footprint

Abeona Therapeutics is headquartered in the United States, with its principal executive offices and core operations located in New York. The company’s research, manufacturing, and corporate functions are primarily domestic, reflecting its development-stage focus and concentration on U.S.-based clinical trials and regulatory engagement.

Internationally, Abeona’s presence is indirect and largely tied to clinical research activities, including trial sites outside the United States and interactions with non-U.S. regulatory authorities. While it does not maintain significant overseas facilities, its therapeutic programs are intended for global rare disease markets, particularly in North America and Europe, where regulatory frameworks for gene therapies are well established.

Leadership & Governance

Abeona is led by an executive team with experience in biotechnology, rare disease drug development, and gene therapy commercialization. The leadership emphasizes scientific rigor, disciplined capital allocation, and long-term value creation through focused pipeline advancement and manufacturing control. Corporate governance follows standard U.S. public company practices, with oversight by an independent board of directors.

Key executives include:

• Joan Fallon – Founder and Chairwoman
• John Maslowski – Chief Executive Officer
• Larry Bock – Chief Financial Officer
• Caroline Beard – Chief Development Officer
• Thomas Chalberg – Chief Scientific Officer